Clamart, France, 03 March 2025 – MicroPort® CRM, a pioneering company in the field of Cardiac Rhythm Management, headquartered in France, is pleased to announce the first patient enrollments in the POLARIS European clinical trial (ClinicalTrials.gov: NCT06453850).This study evaluates the safety and performance of the new FLEXIGO™ delivery catheter system for lead implantation in the interventricular septum, specifically targeting Left Bundle Branch Area Pacing (LBBAP).
LBBAP is an emerging pacing technique that utilizes the heart's natural conduction system efficiency and is recognized as the preferred approach to physiological pacing.
Doctor Ferreira at Coimbra Hospital in Portugal successfully enrolled the first patients. Doctor Cano, Principal Investigator of the POLARIS clinical study also implanted their first patients at the University and Polytechnic La Fe Hospital of Valencia, Spain.
"The FLEXIGO™ catheter demonstrated remarkable precision and stability during implantations, making the procedure both efficient and reliable. This represents a promising advancement in lead delivery for LBBAP." said Dr. Cano.
About MicroPort® CRM
MicroPort® CRM is a pioneering company in the field of Cardiac Rhythm Management (CRM), and a subsidiary of MicroPort Scientific Corporation (stock code: 00853.HK), with world headquarters in Clamart, near Paris, France. Through our long-standing expertise in CRM, MicroPort® CRM develops, manufactures and markets around the world cardiac pacemakers, implantable cardiac defibrillators, cardiac resynchronization systems and ECG diagnostic solutions for the management of cardiac rhythm disorders and heart failure. Our state-of-the-art products are manufactured in Clamart, France, Saluggia, Italy, and in Santo Domingo, Dominican Republic. MicroPort® CRM also distributes MicroPort® solutions in Interventional Cardiology and Electrophysiology in Europe.
For more information, please refer to www.microport.com